登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：603976 公司简称：正川股份 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对公司经营情 况有 ...

正川股份股价报22.24元，较前一交易日下跌0.62元，跌幅2.71%。开盘价为23.38元，最高价23.38元， 最低价22.06元，成交量为42569手，成交额0.96亿元。 8月22日主力资金净流出656.59万元，占流通市值0.2%。近五日主力资金净流出639.41万元，占流通市 值0.19%。 风险提示：投资有风险，入市需谨慎。 正川股份主要从事药用玻璃管制瓶等药用包装材料的研发、生产和销售。公司产品线覆盖0.5ML至 10ML等各类规格，包括预灌封注射器、卡式瓶、免洗免灭西林瓶等高附加值产品。公司业务涉及医疗 器械领域，注册地位于重庆。 公司2025年半年报显示，上半年实现营业收入3.24亿元，归母净利润1408.83万元。经营活动产生的现金 流量净额5936.13万元，同比增长89.31%。公司已在欧洲、南美、东南亚等近20个国家实现销售，并计 划在香港设立全资子公司以拓展国际市场。报告期内，公司新兴业务产销量较去年同期显著增长。 ...

重庆正川医药包装材料股份有限公司2025 年半年度报告 公司代码：603976 公司简称：正川股份 重庆正川医药包装材料股份有限公司 重庆正川医药包装材料股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人邓勇、主管会计工作负责人邓勇及会计机构负责人（会计主管人员）肖汉容声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细 ...

证券代码：603976 证券简称：正川股份 公告编号：2025-053 债券代码：113624 债券简称：正川转债 重庆正川医药包装材料股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重庆正川医药包装材料股份有限公司（以下简称"公司"）为深入贯彻落实 国务院《关于进一步提高上市公司质量的意见》《关于加强监管防范风险推动资 本市场高质量发展的若干意见》要求，积极响应上海证券交易所《关于开展沪市 公司"提质增效重回报"专项行动倡议》，推动公司向高质量发展，切实保障和 维护投资者合法权益，进一步增强投资者信心，结合公司实际，制定了《2025 年度"提质增效重回报"行动方案》，本方案已经公司四届董事会第二十三次会 议审议通过，具体如下： 一、聚焦主业发展，提升经营质量 公司始终聚焦于药用玻璃管制瓶等药用包装材料的研发、生产和销售，公司 是国内药用玻璃行业中同时具备技术、人才、自动化生产及完整的"拉管--制瓶 —制盖"一体化生产企业，具备长期在该领域发展的核心竞争力。公 ...

中国中硼硅玻璃行业上游石英砂龙头企业主要为石英股份，制作管制瓶的玻璃原材料主要来自国际机构康宁 等。上游设备供应企业较多，主要如生产马弗炉的上海恒字等企业，生产拉管机的东莞神龙机械等。行业中 游生产制造企业主要国际企业德国肖特(SCHOTT)公司、美国康宁公司(Corning)、日本NEG 公司(Nippon Electric Glass)和格雷斯海姆公司(Gerresheimer)，国内企业山东药玻、正川股份、沧州四星玻璃、凯盛君 恒、旗滨集团、东旭光电等。 转自：前瞻产业研究院 行业主要上市公司：力诺药包(301188.SZ)、山东药玻(600529.SH)、旗滨集团(601636.SH)、威高股份 (01066.HK)、正川股份(603976.SH)等 本文核心数据：产业链生态图谱;代表性企业产销量 产业链剖析：中游为核心环节 中国中硼硅玻璃行业上游原材料主要包括石英砂、硼砂、碎玻璃、方解石、长石等产品，主要生产设备为马 弗炉和拉管机，除此在制造中硼硅玻璃管/瓶的过程中需要大量电力、水和天然气资源。行业下游应用领域 主要为各大医疗机构和医药销售、物流机构等。 硅玻璃产业链区域热力地图：集中在东部沿海地区 ...

Core Viewpoint - Shanghai Xinyao Paike Medical Technology Co., Ltd. has successfully developed into a leading manufacturer of drug delivery devices, driven by a strong team spirit and a focus on addressing market pain points in the medical device sector [2][4][8]. Company Development - The company was founded by a team with extensive experience in the medical industry, who identified the market's reliance on foreign products and aimed to create high-end drug delivery devices for the Chinese market [4][5]. - Xinyao Paike has expanded its product offerings to include pre-filled syringes and self-injection pens, with a focus on chronic disease management [6][7]. Product Innovation - The company has achieved significant milestones in the development of needle protection devices, capturing over 90% of the domestic market share and establishing partnerships with leading pharmaceutical companies [5][8]. - Xinyao Paike's self-injection pens are designed for patients with chronic diseases, allowing for convenient at-home medication administration [7][8]. Market Strategy - The company emphasizes a market-driven approach to project selection, ensuring that all product developments are aligned with customer needs and market demands [6][8]. - Xinyao Paike has implemented a rigorous project approval process involving multiple departments to ensure the feasibility and foresight of new initiatives [8][9]. Team and Talent Development - The success of Xinyao Paike is attributed to a cohesive and collaborative founding team, which has fostered trust and efficiency in market execution [9]. - The company actively recruits talent through partnerships with educational institutions and industry networks, aiming to build a strong talent pipeline [9]. Future Outlook - Xinyao Paike plans to continue its focus on the drug delivery device sector, enhancing product quality and technology while expanding both domestic and international markets [9].

Core Viewpoint - Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. maintains a long-term credit rating of A+ with a stable outlook, reflecting its competitive position in the pharmaceutical glass bottle manufacturing industry despite recent challenges in revenue and profit due to market fluctuations and policy impacts [1][4]. Company Overview - The company specializes in the research, production, and sales of pharmaceutical glass bottles and related packaging materials, with a registered capital of 151.20 million yuan and a total asset of 19.64 billion yuan as of March 2025 [10][8]. - As of 2024, the company has an annual production capacity of 10.25 billion pharmaceutical glass bottles and 3.40 billion bottle caps, serving nearly a thousand clients, including major pharmaceutical manufacturers [15][14]. Financial Performance - In 2024, the company reported total revenue of 8.01 billion yuan, a decrease of 11.05% year-on-year, and a profit of 0.60 billion yuan [9][10]. - For the first quarter of 2025, revenue further declined by 34.24% year-on-year to 1.62 billion yuan, with profit dropping by 49.45% [4][9]. Market and Industry Analysis - The pharmaceutical packaging materials industry is experiencing pressure from intensified competition and policy changes, such as drug procurement reforms, which have led to reduced demand and pricing pressures [11][12]. - Despite these challenges, the market for pharmaceutical glass, particularly high-quality borosilicate glass, is expected to grow due to increasing healthcare awareness and aging population trends in China [12][13]. Competitive Advantages - The company possesses integrated production capabilities for borosilicate glass bottles, allowing for diversified product offerings and a strong competitive edge in the market [15][14]. - The company has invested in research and development, holding 48 patents, including 8 invention patents, which supports its innovation and product quality [15][14]. Challenges and Risks - The company faces significant risks from fluctuations in raw material and energy costs, which constitute a large portion of its operating expenses [17][7]. - The ongoing volatility in downstream demand, influenced by healthcare policies and market competition, poses a risk to the company's revenue stability [4][11].

Core Viewpoint - Terumo, a Japanese medical device manufacturer, is acquiring a German factory from WuXi Biologics for €150 million, aiming to establish its first overseas CDMO base and target large pharmaceutical orders in Europe by 2030 [1]. Group 1: Acquisition Details - The acquisition amount is €150 million, and the factory covers an area of 13,000 square meters [1]. - Approximately 150 employees will transition to Terumo following the acquisition [1]. - The factory is expected to produce pre-filled syringes, although the production capacity has not been disclosed [1]. Group 2: Strategic Goals - Terumo aims to leverage the German factory as a foothold for expanding its overseas operations, particularly targeting major pharmaceutical companies headquartered in Europe, such as Roche and Novartis [1]. - The company is actively developing its CDMO business to provide integrated solutions for drug-compatible containers and delivery devices [1]. - Terumo plans to enhance the production capacity of its Kofu factory in Yamanashi Prefecture within the fiscal year ending March 2025 [1]. Group 3: Market Position - Currently, Terumo's primary clients are domestic pharmaceutical companies in Japan, but it has secured its first overseas order in 2024 [1].

Core Viewpoint - The company experienced a decline in revenue but improved net profit and gross margin due to a shift in product mix towards higher-margin borosilicate glass products [2][3]. Revenue and Profit Summary - In 2024, the company achieved revenue of 800 million yuan, a year-on-year decrease of 11.1% [2]. - The net profit attributable to shareholders was 50 million yuan, an increase of 32.2% year-on-year [2]. - The non-recurring net profit attributable to shareholders was also 50 million yuan, reflecting a year-on-year increase of 65.1% [2]. - The gross margin improved to 20.7%, up 4.7 percentage points from the previous year, driven by an increase in the proportion of high-margin borosilicate glass products [2]. Product Segment Performance - Borosilicate glass bottles generated revenue of 420 million yuan, down 0.8% year-on-year, with a gross margin of 22.8%, up 8.3 percentage points [2]. - Sodium-calcium glass bottles had revenue of 300 million yuan, a decrease of 16.2%, with a gross margin of 17.5%, up 2.0 percentage points [2]. - Bottle caps generated revenue of 70 million yuan, down 35.7%, with a gross margin of 18.5%, down 1.1 percentage points [2]. Research and Development Investment - The company increased R&D investment to 60 million yuan, a rise of 22.6% year-on-year [3]. - The company completed the full product layout in the pharmaceutical glass bottle sector, achieving large-scale production capabilities for various borosilicate products [3]. Financial Management and Dividends - The company announced a cash dividend plan for 2024, proposing a distribution of 2.46 yuan per 10 shares, which represents 98.3% of the net profit attributable to shareholders [3]. - The sales, management, R&D, and financial expense ratios were 1.8%, 5.4%, 2.5%, and 1.8%, respectively, with variations in each category compared to the previous year [3]. Profit Forecast and Investment Suggestion - The company is expected to benefit from industry growth and the gradual promotion of new products, with projected net profits of 64 million yuan, 74 million yuan, and 85 million yuan for 2025-2027, corresponding to PE ratios of 40, 35, and 30 [4].